FDA approve a shared REMS for all transmucosal fentanyl products
20th February 2012
The US Food and Drug Administration (FDA) have approved a shared Risk Evaluation and Mitigation Strategy (REMS) for all Transmucosal Immediate Release Fentanyl (TIRF) products. This shared program has been designed to streamline the REMS process and will allow prescribers and pharmacists to enrol in one shared REMS system for all TIRF products. The branded fentanyl products currently included are; Abstral (sublingual tablet), Actiq (lozenge), Fentora (buccal tablet), Lazanda (nasal spray), Onsolis (buccal soluble film) and Subsys (sublingual spray), the website will be available in March 2012.
- Lacri-Lube eye ointment recalled
- Update on the prescribing and dispensing of pregabalin for neuropathic pain
- Disipal brand of orphenadrine tablets discontinued
- Cochrane review: venlafaxine for neuropathic pain in adults
- PPIs and subacute cutaneous lupus erythematosus
- Magnesium aspartate dihydrate approved by NHS Wales for hypomagnesaemia
- Capsaicin patch indications updated
- PCF5 - Highly commended by BMA
- PCF5+ 2015 pdf available soon!
- Motor Neurone Disease: NICE guideline consultation